title: Strategic challenges in neurotherapeutic pharmaceutical development.
abstract: Developing new therapeutics presents formidable economic, scientific, and medical challenges that are exacerbated by special factors in neurotherapeutics development, e.g., the complexity of the CNS with its attendant need to sometimes affect multiple pathways, the lack of clarity of disease etiology, inadequacy of available animal models, and difficulties in defining disease populations and quantifying treatment response. This paper reviews the economic challenges faced by therapeutics developers in general and neurotherapeutics developers in particular. It discusses key scientific challenges, particularly those pertinent to neurotherapeutics development, as a background to proposing a different industrial strategy to drive future therapeutics development. This Biodesign strategy potentially surpasses previous paradigms by incorporating elements such as the use of disease modeling to select better targets and potential therapies, information science-based approaches to enhance small molecule chemistry, exploitation of the potential for biological technologies to rapidly generate mechanistic probes, and development of improved approaches for using animal models and studying human molecules mechanistically and biologically. Synergistic use of these elements can change the overall business model of companies engaged in neurotherapeutics development. The Biodesign paradigm has the potential to both markedly enhance the development of new therapies and to address some of the economic challenges facing healthcare systems and therapeutics developers alike.
authors.affiliation: Clinical Research and Development, Wyeth Pharmaceuticals, Collegeville, Pennsylvania 19426, USA. gallenc@wyeth.com
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Gallen
mesh_terms: D000818:Animals; D002490:Central Nervous System / Q000187:drug effects*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D008959:Models, Neurological; D013678:Technology, Pharmaceutical / Q000191:economics / Q000379:methods
references.citation: Food Drug Law J. 1997;52(2):163-7
references.pmid: 10557553
references.citation: J Health Econ. 1994 Dec;13(4):383-406
references.pmid: 10140531
references.citation: Nat Rev Drug Discov. 2003 Feb;2(2):151-4
references.pmid: 12563306
references.citation: Clin Liver Dis. 2003 May;7(2):369-79, vi
references.pmid: 12879989
references.citation: Science. 2000 Mar 17;287(5460):1964-9
references.pmid: 10720315
references.citation: Pharmacoeconomics. 2002;20 Suppl 3:11-29
references.pmid: 12457422
references.citation: Arch Dis Child. 2001 Jul;85(1):62-6
references.pmid: 11420207
references.citation: J Health Econ. 2003 Mar;22(2):151-85
references.pmid: 12606142
references.citation: Drug Discov Today. 2003 Mar 1;8(5):212-21
references.pmid: 12634013
references.citation: Sci Am. 2003 Feb;288(2):18-9
references.pmid: 12561454
references.citation: Nat Biotechnol. 2001 Dec;19(12):1099-100
references.pmid: 11731767
references.citation: Science. 2000 Mar 17;287(5460):1960-4
references.pmid: 10720314
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17107-12
references.pmid: 12475933
references.citation: Int J Hematol. 2002 Aug;76 Suppl 2:83-9
references.pmid: 12430905
references.citation: Nat Biotechnol. 1997 Dec;15(13):1318-9
references.pmid: 9415870
references.citation: Drug Discov Today. 2003 Mar 1;8(5):203-11
references.pmid: 12634012
references.citation: Nature. 2002 Jan 3;415(6867):8-9
references.pmid: 11780081
references.citation: Dev Biol Stand. 1998;96:97-104
references.pmid: 9890522